Prestige Wealth Management Group’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-13
Closed -$1K 1075
2022
Q1
$1K Hold
13
﹤0.01% 938
2021
Q4
$2K Sell
13
-33
-72% -$5.05K ﹤0.01% 839
2021
Q3
$6K Sell
46
-2
-4% -$343 ﹤0.01% 608
2021
Q2
$9K Buy
48
+25
+109% +$4.52K ﹤0.01% 503
2021
Q1
$4K Hold
23
﹤0.01% 689
2020
Q4
$3K Hold
23
﹤0.01% 716
2020
Q3
$3K Buy
23
+8
+53% +$840 ﹤0.01% 649
2020
Q2
$1K Hold
15
﹤0.01% 851
2020
Q1
$1K Buy
+15
New +$1.17K ﹤0.01% 854

Other funds holding TXG

Prestige Wealth Management Group's TXG Position: Q2 2022 in Review

Prestige Wealth Management Group sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 13 shares — an estimated $1K sold.

Prestige Wealth Management Group first reported a position in TXG in Q1 2020 and held it in 9 quarters. The position peaked at $9K in Q2 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • Prestige Wealth Management Group reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • Prestige Wealth Management Group sold 13 10x Genomics shares in Q2 2022, an estimated $1K.
  • Prestige Wealth Management Group first reported a position in 10x Genomics in Q1 2020 and held it in 9 quarters.
  • Prestige Wealth Management Group's 10x Genomics position peaked at $9K in Q2 2021.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Prestige Wealth Management Group's 13F filing for Q2 2022, filed 10 Aug 2022.